Articles related to BLEEDING/BLOOD DISORDERS

The study found that andexanet alfa significantly improves hemostatic efficacy in patients with intracerebral hemorrhage on factor Xa inhibitors but increases the risk of thrombotic events. These findings highlight the need for careful patient selection and monitoring when considering andexanet alfa in clinical practice.

The introduction of exa-cel as a gene-editing therapy marks a significant advance in treating hemoglobinopathies, offering new hope for patients with SCD and β-thalassemia. This treatment focuses on reactivating fetal hemoglobin to mitigate disease symptoms effectively.

In a recent study, 91% of patients with transfusion-dependent β-thalassemia achieved independence from transfusions following treatment with Exagamglogene Autotemcel.

Primary care physicians are crucial in managing the intricate health complications of allogeneic HCT survivors, including chronic graft-vs-host disease and increased cardiovascular risks.

In the recent phase 3 trial, recombinant ADAMTS13 demonstrated a profound capability to maintain ADAMTS13 activity at approximately 100% of normal levels, highlighting its potential to substantially reduce thrombotic complications in patients with congenital TTP.

Vigilant history-taking and toxicological scrutiny are paramount in diagnosing potentially fatal drug-induced oxidative hemolysis, saving lives through early intervention.